PL1896470T3 - Pochodne pirolopirydynowe jako inhibitory kinazy białkowej - Google Patents

Pochodne pirolopirydynowe jako inhibitory kinazy białkowej

Info

Publication number
PL1896470T3
PL1896470T3 PL06759904T PL06759904T PL1896470T3 PL 1896470 T3 PL1896470 T3 PL 1896470T3 PL 06759904 T PL06759904 T PL 06759904T PL 06759904 T PL06759904 T PL 06759904T PL 1896470 T3 PL1896470 T3 PL 1896470T3
Authority
PL
Poland
Prior art keywords
compounds
protein kinase
kinase inhibitors
pyrrolopyridine derivatives
disorders
Prior art date
Application number
PL06759904T
Other languages
English (en)
Inventor
Barun Okram
Pingda Ren
Nathanael S Gray
Original Assignee
Irm Llc
Scripps Research Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Irm Llc, Scripps Research Inst filed Critical Irm Llc
Publication of PL1896470T3 publication Critical patent/PL1896470T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A61P5/16—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4 for decreasing, blocking or antagonising the activity of the thyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurosurgery (AREA)
  • Oncology (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Enzymes And Modification Thereof (AREA)
PL06759904T 2005-05-16 2006-05-15 Pochodne pirolopirydynowe jako inhibitory kinazy białkowej PL1896470T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US68185305P 2005-05-16 2005-05-16
PCT/US2006/018868 WO2006124863A2 (en) 2005-05-16 2006-05-15 Pyrrolopyridine derivatives as protein kinase inhibitors
EP06759904A EP1896470B1 (en) 2005-05-16 2006-05-15 Pyrrolopyridine derivatives as protein kinase inhibitors

Publications (1)

Publication Number Publication Date
PL1896470T3 true PL1896470T3 (pl) 2011-03-31

Family

ID=37076087

Family Applications (1)

Application Number Title Priority Date Filing Date
PL06759904T PL1896470T3 (pl) 2005-05-16 2006-05-15 Pochodne pirolopirydynowe jako inhibitory kinazy białkowej

Country Status (16)

Country Link
US (1) US20080300267A1 (pl)
EP (1) EP1896470B1 (pl)
JP (1) JP2008540664A (pl)
KR (1) KR20080016643A (pl)
CN (1) CN101218241B (pl)
AT (1) ATE469151T1 (pl)
AU (1) AU2006247322A1 (pl)
BR (1) BRPI0610828A2 (pl)
CA (1) CA2608333A1 (pl)
DE (1) DE602006014540D1 (pl)
ES (1) ES2345629T3 (pl)
MX (1) MX2007014327A (pl)
PL (1) PL1896470T3 (pl)
PT (1) PT1896470E (pl)
RU (1) RU2387653C2 (pl)
WO (1) WO2006124863A2 (pl)

Families Citing this family (91)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2311837B1 (en) 2004-03-30 2014-05-21 Vertex Pharmaceuticals Inc. Azaindoles useful as inhibitors of jak and other protein kinases
US7361764B2 (en) 2004-07-27 2008-04-22 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US7709645B2 (en) 2004-07-27 2010-05-04 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
AU2005269386A1 (en) 2004-07-27 2006-02-09 Sgx Pharmaceuticals, Inc. Pyrrolo-pyridine kinase modulators
US7452993B2 (en) 2004-07-27 2008-11-18 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
US7626021B2 (en) 2004-07-27 2009-12-01 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
RU2435769C2 (ru) * 2005-05-20 2011-12-10 Вертекс Фармасьютикалз Инкорпорейтед Пирролопиридины, полезные в качестве ингибиторов протеинкиназы
JP5591471B2 (ja) 2006-01-17 2014-09-17 バーテックス ファーマシューティカルズ インコーポレイテッド ヤヌスキナーゼ阻害剤として有用なアザインドール
DE102006012617A1 (de) * 2006-03-20 2007-09-27 Merck Patent Gmbh 4-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
WO2007135398A1 (en) * 2006-05-22 2007-11-29 Astrazeneca Ab Indole derivatives
MX2009004771A (es) * 2006-11-01 2009-06-17 Vertex Pharma Compuestos heteroaril triciclicos utiles como inhibidores de janus cinasa.
JP5179509B2 (ja) * 2006-12-08 2013-04-10 エフ．ホフマン−ラ ロシュ アーゲー 置換ピリミジン類及びｊｎｋモジュレーターとしてのこれらの使用
JP5406039B2 (ja) 2006-12-21 2014-02-05 バーテックス ファーマシューティカルズ インコーポレイテッド タンパク質キナーゼ阻害剤として有用な５−シアノ−４−（ピロロ［２，３ｂ］ピリジン−３−イル）−ピリミジン誘導体
MX2009006535A (es) * 2006-12-22 2009-06-26 Novartis Ag Derivados de indol-4-il-pirimidinil-2-il-amina y su uso como inhibidores de cinasa dependiente de ciclina.
FR2912744B1 (fr) * 2007-02-16 2012-09-07 Centre Nat Rech Scient Composes pyrrolo°2,3-b!pyridine,composes azaindoles utiles dans la synthese de ces composes pyrrolo°2,3-b!pyridine, leurs procedes de fabrication et leurs utilisations.
US8242280B2 (en) 2007-04-10 2012-08-14 Sgx Pharmaceuticals, Inc. Fused ring heterocycle kinase modulators
TW200908968A (en) 2007-05-29 2009-03-01 Sgx Pharmaceuticals Inc Substituted pyrrolopyridines and pyrazolopyridines as kinase modulators
DK2478905T3 (da) * 2007-06-01 2014-06-30 Wyeth Llc Behandling af imatinib-resistent leukæmi under anvendelse af 4-aminoquinolin-3-carbonitriler
GB0710528D0 (en) * 2007-06-01 2007-07-11 Glaxo Group Ltd Novel compounds
DE102007028515A1 (de) 2007-06-21 2008-12-24 Merck Patent Gmbh 6-(Pyrrolopyridinyl)-pyrimidinyl-2-amin-derivate
US8173635B2 (en) * 2007-11-02 2012-05-08 Vertex Pharmaceuticals Incorporated Kinase inhibitors
BRPI0907236A2 (pt) * 2008-01-22 2017-06-06 Merck Patent Ges Mit Berschränkter Haftung inibidores de proteína quinase e uso dos mesmos
US9273077B2 (en) 2008-05-21 2016-03-01 Ariad Pharmaceuticals, Inc. Phosphorus derivatives as kinase inhibitors
WO2009143389A1 (en) 2008-05-21 2009-11-26 Ariad Pharmaceuticals, Inc. Phosphorous derivatives as kinase inhibitors
AU2009262199B2 (en) 2008-06-27 2012-08-09 Amgen Inc. Ang-2 inhibition to treat multiple sclerosis
DE102008031517A1 (de) * 2008-07-03 2010-01-07 Merck Patent Gmbh Pyrrolopyridinyl-pyrimidin-2-yl-amin-derivate
MX2011000839A (es) * 2008-07-23 2011-04-05 Vertex Pharma Inhibidores de pirazolpiridina cinasa.
MX2011000843A (es) * 2008-07-23 2011-04-11 Vertex Pharma Inhibidores de pirazolopiridin cinasa triciclicos.
CN101723936B (zh) * 2008-10-27 2014-01-15 上海睿星基因技术有限公司 激酶抑制剂及其在药学中的用途
MX2011011653A (es) 2009-05-06 2012-01-20 Vertex Pharma Pirazolopiridinas.
KR102001418B1 (ko) 2009-05-26 2019-07-19 애브비 아일랜드 언리미티드 컴퍼니 암，면역 질환 및 자가면역 질환의 치료를 위한 아폽토시스-유도제
US20220315555A1 (en) 2009-05-26 2022-10-06 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
US9034875B2 (en) 2009-05-26 2015-05-19 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
US8546399B2 (en) * 2009-05-26 2013-10-01 Abbvie Inc. Apoptosis inducing agents for the treatment of cancer and immune and autoimmune diseases
NZ597059A (en) 2009-06-17 2014-01-31 Vertex Pharma Inhibitors of influenza viruses replication
PL2452940T3 (pl) * 2009-07-10 2015-05-29 Taiho Pharmaceutical Co Ltd Związek azabicykliczny i jego sól
CA2767089A1 (en) * 2009-07-15 2011-01-20 Abbott Laboratories Pyrrolopyridine inhibitors of kinases
DE102009060175A1 (de) * 2009-12-23 2011-06-30 Merck Patent GmbH, 64293 Pyrrolo[2,3-d] pyrazin-7-yl-pyrimidin-Verbindungen
EP2519517B1 (en) 2009-12-29 2015-03-25 Dana-Farber Cancer Institute, Inc. Type ii raf kinase inhibitors
MX2012008641A (es) 2010-01-27 2012-11-23 Vertex Pharma Inhibidores de cinasas de pirazolopirazinas.
CA2787315A1 (en) 2010-01-27 2011-08-04 Vertex Pharmaceuticals Incorporated Pyrazolopyridine kinase inhibitors
MX2012008643A (es) 2010-01-27 2013-02-26 Vertex Pharma Inhibidores de cinasas de pirazolopiridinas.
CA2811805A1 (en) 2010-10-29 2012-05-03 Abbvie Inc. Solid dispersions containing an apoptosis-inducing agent
UA113500C2 (xx) 2010-10-29 2017-02-10 Одержані екструзією розплаву тверді дисперсії, що містять індукуючий апоптоз засіб
EP2642999B1 (en) 2010-11-23 2016-09-28 AbbVie Bahamas Ltd. Methods of treatment using selective bcl-2 inhibitors
RU2628560C2 (ru) 2010-11-23 2017-08-18 Эббви Инк. Соли и кристаллические формы индуцирующего апоптоз агента
WO2012083122A1 (en) * 2010-12-16 2012-06-21 Vertex Pharmaceutical Incorporated Inhibitors of influenza viruses replication
RU2013132681A (ru) 2010-12-16 2015-01-27 Вертекс Фармасьютикалз Инкорпорейтед Ингибиторы репликации вирусов гриппа
MX2013006846A (es) * 2010-12-16 2013-12-16 Vertex Pharma Inhibidores de la replicacion de los virus de la influenza.
JP5999177B2 (ja) 2011-05-04 2016-09-28 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
UA118010C2 (uk) 2011-08-01 2018-11-12 Вертекс Фармасьютікалз Інкорпорейтед Інгібітори реплікації вірусів грипу
US9382239B2 (en) 2011-11-17 2016-07-05 Dana-Farber Cancer Institute, Inc. Inhibitors of c-Jun-N-terminal kinase (JNK)
US10138235B2 (en) 2011-12-14 2018-11-27 Sanofi Pyrazolopyridine derivatives, preparation process therefor and therapeutic use thereof
FR2984325A1 (fr) * 2011-12-14 2013-06-21 Sanofi Sa Derives de pyrazolopyridine, leur procede de preparation et leur application en therapeutique
EP2809671B1 (en) * 2012-01-30 2016-01-13 Cephalon, Inc. Imidazo [4, 5 - b]pyridine derivatives as alk and jak modulators for the treatment of proliferative disorders
JP6469567B2 (ja) 2012-05-05 2019-02-13 アリアド・ファーマシューティカルズ・インコーポレイテッド Ｅｇｆｒ発動性がんの細胞増殖阻害用化合物
CA2871388A1 (en) * 2012-06-27 2014-01-03 F. Hoffmann-La Roche Ag 5-azaindazole compounds and methods of use
WO2014063068A1 (en) 2012-10-18 2014-04-24 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (cdk7)
USRE48175E1 (en) 2012-10-19 2020-08-25 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged small molecules as inducers of protein degradation
WO2014063054A1 (en) 2012-10-19 2014-04-24 Dana-Farber Cancer Institute, Inc. Bone marrow on x chromosome kinase (bmx) inhibitors and uses thereof
FR3000493A1 (fr) * 2012-12-28 2014-07-04 Oribase Pharma Nouveaux inhibiteurs de proteines kinases
EP2964225B1 (en) * 2013-03-06 2018-08-08 Allosteros Therapeutics Inc. CaMKII INHIBITORS AND USES THEREOF
US20140275082A1 (en) 2013-03-14 2014-09-18 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
WO2014155300A2 (en) * 2013-03-28 2014-10-02 Aurigene Discovery Technologies Limited Substitued pyrimidine amine derivatives as tak-1 inhibitors
US9611283B1 (en) 2013-04-10 2017-04-04 Ariad Pharmaceuticals, Inc. Methods for inhibiting cell proliferation in ALK-driven cancers
CA2927917C (en) 2013-10-18 2022-08-09 Syros Pharmaceuticals, Inc. Heteroaromatic compounds useful for the treatment of proliferative diseases
CN105849099B (zh) 2013-10-18 2020-01-17 达纳-法伯癌症研究所股份有限公司 周期蛋白依赖性激酶7(cdk7)的多环抑制剂
HUE052178T2 (hu) 2013-11-13 2021-04-28 Vertex Pharma Eljárások influenzavírus-replikáció inhibitorainak elõállítására
SG10201804026WA (en) 2013-11-13 2018-06-28 Vertex Pharma Inhibitors of influenza viruses replication
CN104860941B (zh) * 2014-02-25 2017-03-22 上海海雁医药科技有限公司 2,4‑二取代苯‑1,5‑二胺衍生物及其应用以及由其制备的药物组合物和药用组合物
WO2015164604A1 (en) 2014-04-23 2015-10-29 Dana-Farber Cancer Institute, Inc. Hydrophobically tagged janus kinase inhibitors and uses thereof
US10017477B2 (en) 2014-04-23 2018-07-10 Dana-Farber Cancer Institute, Inc. Janus kinase inhibitors and uses thereof
EP3189052B1 (en) * 2014-09-05 2021-11-03 The Johns Hopkins University Camkii inhibitors and uses thereof
MA40772A (fr) 2014-10-02 2017-08-08 Vertex Pharma Variants du virus de la grippe a
MA40773A (fr) 2014-10-02 2017-08-08 Vertex Pharma Variants du virus influenza a
EP3236948A4 (en) * 2014-12-23 2018-10-03 Millennium Pharmaceuticals, Inc. Combination of raf inhibitors and aurora kinase inhibitors
AU2015371251B2 (en) 2014-12-23 2020-06-11 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinase 7 (CDK7)
EP3273966B1 (en) 2015-03-27 2023-05-03 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
MA42422A (fr) 2015-05-13 2018-05-23 Vertex Pharma Inhibiteurs de la réplication des virus de la grippe
WO2016183116A1 (en) 2015-05-13 2016-11-17 Vertex Pharmaceuticals Incorporated Methods of preparing inhibitors of influenza viruses replication
US10702527B2 (en) 2015-06-12 2020-07-07 Dana-Farber Cancer Institute, Inc. Combination therapy of transcription inhibitors and kinase inhibitors
EP3347018B1 (en) 2015-09-09 2021-09-01 Dana-Farber Cancer Institute, Inc. Inhibitors of cyclin-dependent kinases
JP7352284B2 (ja) * 2017-05-15 2023-09-28 ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・ミシガン ＬＳＤ－１インヒビターとしてのピロロ〔２，３－ｃ〕ピリジン及び関連類似体
WO2020005807A1 (en) 2018-06-25 2020-01-02 Dana-Farber Cancer Institute, Inc. Taire family kinase inhibitors and uses thereof
JP7660063B2 (ja) 2018-12-28 2025-04-10 ダナ－ファーバー キャンサー インスティテュート， インコーポレイテッド サイクリン依存性キナーゼ７のインヒビターおよびそれらの使用
CN112142731B (zh) * 2019-06-28 2022-07-22 成都赜灵生物医药科技有限公司 一种2，4-二取代嘧啶衍生物及其制备方法和用途
MX2022001115A (es) * 2019-07-29 2022-05-03 Heparegenix Gmbh Inhibidores de proteina quinasa de pirazolo-piridina sustituida con heteroarilo para promover la regeneracion hepatica o reducir o prevenir la muerte de hepatocito.
CN110627775B (zh) * 2019-10-24 2026-01-30 特科罗生物科技(成都)有限公司 一种小分子化合物
CN114452392B (zh) * 2022-02-07 2024-06-18 孙良丹 用于抑制camk2g表达的制剂在制备用于治疗银屑病的药剂中的应用
CN115785134B (zh) * 2022-10-28 2023-08-29 浙大城市学院 一种含氮杂环的硼酸化合物及制备方法和应用
US12269826B1 (en) * 2023-11-16 2025-04-08 King Faisal University 7H-pyrido[4′,3′:4,5]pyrrolo[2,3-c][1,7]naphthyridine compounds as CK2 inhibitors

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998047899A1 (en) * 1997-04-24 1998-10-29 Ortho-Mcneil Corporation, Inc. Substituted pyrrolopyridines useful in the treatment of inflammatory diseases
AU2001270783B2 (en) * 2000-07-11 2006-06-15 Pharma Mar, S.A. Variolin derivatives as anti-cancer agents
SE0202463D0 (sv) * 2002-08-14 2002-08-14 Astrazeneca Ab Novel compounds
EP2311837B1 (en) * 2004-03-30 2014-05-21 Vertex Pharmaceuticals Inc. Azaindoles useful as inhibitors of jak and other protein kinases
WO2006050076A1 (en) * 2004-10-29 2006-05-11 Janssen Pharmaceutica, N.V. Pyrimidinyl substituted fused-pyrrolyl compounds useful in treating kinase disorders

Also Published As

Publication number Publication date
EP1896470A2 (en) 2008-03-12
JP2008540664A (ja) 2008-11-20
ATE469151T1 (de) 2010-06-15
EP1896470B1 (en) 2010-05-26
CN101218241A (zh) 2008-07-09
ES2345629T3 (es) 2010-09-28
RU2387653C2 (ru) 2010-04-27
BRPI0610828A2 (pt) 2010-07-27
WO2006124863A2 (en) 2006-11-23
MX2007014327A (es) 2008-02-11
CN101218241B (zh) 2011-02-16
KR20080016643A (ko) 2008-02-21
CA2608333A1 (en) 2006-11-23
WO2006124863A3 (en) 2007-01-25
US20080300267A1 (en) 2008-12-04
PT1896470E (pt) 2010-08-26
RU2007146390A (ru) 2009-06-27
DE602006014540D1 (en) 2010-07-08
AU2006247322A1 (en) 2006-11-23

Similar Documents

Publication Publication Date Title
PL1896470T3 (pl) Pochodne pirolopirydynowe jako inhibitory kinazy białkowej
TW200637547A (en) Compounds and compositions as protein kinase inhibitors
TNSN06053A1 (en) 6-substituted anilino purines as rtk inhibitors
MX2009004716A (es) Compuestos y composiciones en la forma de inhibidores de quinasa de proteina.
MX2009011951A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
MXPA05010711A (es) Compuestos y composiciones novedosos como inhibidores de proteina-quinasa.
MX2009011950A (es) Derivados de pirimidina y composiciones como inhibidores de cinasa c-kit y pdgfr.
MX2008002165A (es) Compuestos y composiciones como inhibidores de la proteina cinasa.
WO2004078682A3 (en) Cyclic compounds and compositions as protein kinase inhibitors
NO20071915L (no) Diaminotriazolforbindelser nyttige som proteinkinaseinhibitorer
TW200801008A (en) Protein kinase inhibitors
TW200610762A (en) Compounds and compositions as protein kinase inhibitors
WO2009097287A9 (en) Compounds and compositions as kinase inhibitors
BRPI0517015A (pt) compostos e composições como inibidores de atividade de receptor 1 de canabinóide
MX2009011952A (es) Compuestos y composiciones como inhibidores de cinasa c-kit y pdgfr.
TN2012000081A1 (en) Compounds and compositions as protein kinase inhibitors
MX2009007944A (es) Compuestos y composiciones de purina como inhibidores de quinasa para el tratamiento de enfermedades relacionadas con plasmodium.
MX2009006170A (es) Compuestos y composiciones como inhibidores de cinasa.
PL1899329T3 (pl) Pirymidyno-podstawione pochodne benzimidazolu jako inhibitory kinaz białkowych
IL184898A0 (en) Pyrrolopyrimidine derivatives and pharmaceutical compositions containing the same
IL188942A0 (en) Benzimidazole derivatives and pharmaceutical compositions containing the same
MX2007004248A (es) Derivados heterociclicos de bisarilurea sustituidos como inhibidores de cinasa.
WO2005039486A3 (en) Compounds and compositions as protein kinase inhibitors
MX2008001605A (es) Compuestos y composiciones de tiazol-2-il amino 5-substituido como inhibidores de cinasa proteica.
TW200621711A (en) 3-substituted-5- and 6-aminoalkyl indole-2-carboxylic acid amides and related analogs as inhibitors of casein kinase I ε